WITH YOUR SUPPORT, WE DONATED $200,000 TO LBD RESEARCH AT STANFORD
Stanford Medicine, Poston Lab | Neurology and Neuroscience
Support The Sue Berghoff
LBD Research Fellowship Fund
We established our fund at Stanford after learning about the university’s meaningful and innovative work to advance research of neurodegenerative diseases such as Lewy Body Dementia, Alzheimer’s and Parkinson’s disease. We are proud to partner with an organization that demonstrates the essential nature of sustained commitment in the face of a complex challenge such as dementia.
Dementia, whether in the form of Lewy Body Dementia, Alzheimer’s or another neurodegenerative disease, is in fact a public health crisis. The number of Americans over age 65 who are living with these diseases doubles every five years. By 2050, dementia will be a fact of life for over 15 million Americans. Despite these staggering numbers, the general public lacks awareness of the critical and urgent need for dementia research. Until researchers are better supported in their work to find the causes and cures for Lewy Body Dementia and other forms of dementia, families will continue to be robbed of the quality of life, dignity and hope they so deserve.
In 2019, we met our goal to raise $200,000 for focused Lewy Body Dementia research at Stanford. The Sue’s Story Project is thankful for generous donors and partners who joined us in supporting endeavors at Stanford’s Poston Lab to advance medical research toward a cure. Our shared vision is a world free of all dementia.
LEWY BODY DEMENTIA
Unlocking a fatal brain disease to find answers and a cure
by Dr. Kathleen Poston
Dementia is among the nation’s fastest increasing causes of death and Disability-Adjusted Life Years*, and Lewy Body Dementia (LBD) is the second most common neurodegenerative cause of dementia. Thus, LBD is a looming public health crisis.
Unfortunately, current clinical and biological assessments cannot accurately diagnose people with LBD, nor can they predict how quickly the dementia symptoms will progress. Moreover, brain autopsies have revealed several different pathologies that likely contribute to the clinical symptoms experienced by patients. Thus, there is considerable urgency to identify a biomarker (clinical or biological marker) with three outcomes in mind:
- to help accurately diagnose LBD patients,
- to help predict the clinical symptoms a patient might experience, and
- to help identify the underlying brain changes or pathology causing the LBD symptoms.
The goal of the Poston Lab is to have a full-time post-doctoral Research Fellow dedicated to biomarker discovery in people with LBD.
Our Lab leverages existing Stanford-specific research infrastructure from the Stanford Alzheimer’s disease Research Center and the Pacific Udall Center for Excellence in Parkinson’s Research. These Centers collect in-depth clinical, biological, and imaging data on people with Alzheimer’s disease and Parkinson’s disease, people with Lewy Body Dementia, and older adults with no neurological problems.
Our dedicated Research Fellow would use this data, aiming to identify a biomarker that would improve diagnostic accuracy, predict clinical symptoms, or identify underlying pathology. Such a biomarker is critical to the success of future LBD-specific clinical trials, which are critical to the development of potential therapies and a cure.
*Disability-adjusted Life Years: a measure of overall disease burden, expressed as the number of years lost due to ill-health, disability or early death. who.int/healthinfo/global_burden_disease/metrics_daly/en/
“As a physician, it is devastating to watch your patient succumb to dementia, knowing there is nothing you can do to stop or slow the inevitable decay of the mind. My patients with LBD often seem to be the hardest hit, compared to other causes of dementia, since LBD impacts thinking and behavior in addition to movement. These experiences as a physician fuel my motivation as a scientist to dedicate a fellow in my lab to biomarker development that will ultimately change the experience of dementia in patients with LBD.”
—Dr. Kathleen Poston, Stanford
About Dr. Poston
Dr. Kathleen Poston is Associate Professor of Neurology at Stanford University. She completed her Movement Disorders fellowship training at Columbia University and a post-doctoral research fellowship at the Feinstein Institute, joining the Stanford faculty in 2009. She is Co-Director, Stanford Lewy Body Dementia Research Center of Excellence; Clinical Core Leader, Pacific Udall Center at Stanford; and Clinical Core Co-Leader of the Stanford ADRC. Dr. Poston’s research lab (Poston Lab) is focused on understanding cognitive and other non-motor impairments that develop in patients with Lewy body pathology.